Inventor

ZHANG DON

US17 patents

⚠️ This page may combine multiple inventors who share the name “ZHANG DON”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ZHANG DON

BETA PHARMA INC

2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof

2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof

Fused quinazoline derivatives useful as tyrosine kinase inhibitors

Substituted 2-anilinopyrimidine derivatives as EGFR modulators

Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof

Substituted 2-anilinopyrimidine derivatives as EGFR modulators

2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof

Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof

2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers

Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors

Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof

Aspiration and biopsy needle apparatus and devices and applications thereof

WANG YINXIANG

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof

ZHANG DON

Indolinone protein kinase inhibitors